A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/39 (2006.01) A61K 39/21 (2006.01) A61P 33/06 (2006.01) C07K 14/16 (2006.01)
Patent
CA 2376992
A vaccine formulation for the prevention or amelioration of HIV infection in humans is provided. The vaccine comprises an HIV antigen, especially a protein which comprises Nef and/or Tat of HIV, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the HIV antigen.
L'invention concerne une formulation de vaccin destinée à la prévention ou l'amélioration d'infections à VIH chez des sujets humains. Le vaccin contient un antigène du VIH, notamment une protéine contenant Nef et/ou Tat du VIH, ainsi qu'un oligonucléotide CpG immunostimulant. L'invention concerne également des méthodes de production de la formulation de vaccin de l'invention. Des patients peuvent également être traités par préadministration de l'oligonucléotide CpG avant l'administration de l'antigène du VIH.
Garcon Nathalie
Voss Gerald
Borden Ladner Gervais Llp
Smithkline Beecham Biologicals S.a.
LandOfFree
Use of cpg as an adjuvant for hiv vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cpg as an adjuvant for hiv vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cpg as an adjuvant for hiv vaccine will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1629005